Search results for "Lactams"

showing 10 items of 54 documents

Gut microbiota disturbance during antibiotic therapy: a multi-omic approach

2014

It is known that the gastrointestinal tract (GIT) microbiota responds to different antibiotics in different ways and that while some antibiotics do not induce disturbances of the community, others drastically influence the richness, diversity, and prevalence of bacterial taxa. However, the metabolic consequences thereof, independent of the degree of the community shifts, are not clearly understood. In a recent article, we used an integrative OMICS approach to provide new insights into the metabolic shifts caused by antibiotic disturbance. The study presented here further suggests that specific bacterial lineage blooms occurring at defined stages of antibiotic intervention are mostly associa…

MaleAnabolismAntibioticsGene ExpressionGut floraGastrointestinal FunctionBioinformaticsprokaryotesFecesRNA Ribosomal 16SSystems and Synthetic Biologyhuman fecal microbiota1506MetaproteomicGut Microbiotadatabase2. Zero hungerlong-term impactsGastrointestinal tract0303 health sciencesSysteem en Synthetische Biologiehuman intestinal microbiotabiologyMicrobiotaGastroenterologyBiodiversity3. Good healthAnti-Bacterial AgentsBacterial Typing TechniquesArticle AddendumRNA BacterialInfectious DiseasesMetabolomecommunitymetaproteomicsHuman gut microbiotaMicrobiology (medical)DNA BacterialDisturbance (geology)medicine.drug_classperturbationMetabolomicbeta-LactamsMicrobiologyMicrobiologyresistance03 medical and health sciencesMetagenomicAntibiotic therapyMetabolomemedicineHumans030304 developmental biologyAgedVLAGBacteria030306 microbiologyGene Expression ProfilingColonic MicrofloraAkkermansiaAntibiotic therapybiology.organism_classificationGastrointestinal TractEnterococcusGene Expression RegulationMetaproteomicsMetatranscriptomicGastrointestinal functionmetabolismMeta-Analysis
researchProduct

Synergistic effect between amoxicillin and TLR ligands on dendritic cells from amoxicillin-delayed allergic patients.

2013

Journal Article; Amoxicillin, a low-molecular-weight compound, is able to interact with dendritic cells inducing semi-maturation in vitro. Specific antigens and TLR ligands can synergistically interact with dendritic cells (DC), leading to complete maturation and more efficient T-cell stimulation. The aim of the study was to evaluate the synergistic effect of amoxicillin and the TLR2, 4 and 7/8 agonists (PAM, LPS and R848, respectively) in TLR expression, DC maturation and specific T-cell response in patients with delayed-type hypersensitivity (DTH) reactions to amoxicillin. Monocyte-derived DC from 15 patients with DTH to amoxicillin and 15 controls were cultured with amoxicillin in the pr…

MaleCélulas dendríticasmedicine.medical_treatmentLymphocyte proliferationPharmacology:Chemicals and Drugs::Chemical Actions and Uses::Specialty Uses of Chemicals::Laboratory Chemicals::Ligands [Medical Subject Headings]Monocytes:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]:Phenomena and Processes::Physiological Phenomena::Pharmacological Phenomena::Pharmacological Processes::Drug Interactions::Drug Synergism [Medical Subject Headings]Cells CulturedAmoxicilinaMultidisciplinarymedicine.diagnostic_testChemistryQRLinfocitosImidazolesCitocinasMiddle AgedHumanosCytokineMedicineCytokinesFemaleDrug EruptionsResearch Article:Diseases::Skin and Connective Tissue Diseases::Skin Diseases::Exanthema [Medical Subject Headings]AdultSinergismo medicamentosoScienceFlow cytometryHipersensibilidad retardada:Chemicals and Drugs::Organic Chemicals::Amides::Lactams::beta-Lactams::Penicillins::Penicillin G::Ampicillin::Amoxicillin [Medical Subject Headings]Immune systemAntigen:Diseases::Immune System Diseases::Hypersensitivity::Hypersensitivity Delayed [Medical Subject Headings]ExantemamedicineHypersensitivity:Anatomy::Cells::Blood Cells::Leukocytes::Leukocytes Mononuclear::Lymphocytes [Medical Subject Headings]HumansLigandos:Chemicals and Drugs::Amino Acids Peptides and Proteins::Peptides::Intercellular Signaling Peptides and Proteins::Cytokines [Medical Subject Headings]:Anatomy::Cells::Antigen-Presenting Cells::Dendritic Cells [Medical Subject Headings]TLR9AmoxicillinTLR7Dendritic CellsToll-Like Receptor 2TLR2ImmunologyPloS one
researchProduct

DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current -Lactam Antibiotic Doses Sufficient for Critically Ill Patients?

2014

Background. Morbidity and mortality for critically ill patients with infections remains a global healthcare problem. We aimed to determine whether α-lactam antibiotic dosing in critically ill patients achieves concentrations associated with maximal activity and whether antibiotic concentrations affect patient outcome.Methods. This was a prospective, multinational pharmacokinetic point-prevalence study including 8 α-lactam antibiotics. Two blood samples were taken from each patient during a single dosing interval. The primary pharmacokinetic/pharmacodynamic targets were free antibiotic concentrations above the minimum inhibitory concentration (MIC) of the pathogen at both 50% (50% f TMIC) an…

MaleInternational CooperationAntibioticsadverse eventintensive care unitlaw.invention0302 clinical medicinemeropenemModels[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesadverse events; continuous infusion; extended infusion; pharmacodynamics; pharmacokinetics; Aged; Anti-Bacterial Agents; Bacterial Infections; Blood Chemical Analysis; Female; Humans; Intensive Care Units; International Cooperation; Male; Microbial Sensitivity Tests; Middle Aged; Models Statistical; Prospective Studies; Treatment Outcome; beta-Lactams; Critical Illnessantibiotic therapyProspective Studiesamoxicillin plus clavulanic acidComputingMilieux_MISCELLANEOUSbeta lactam antibioticAPACHE0303 health sciencescritical illneadultclinical trial3. Good healthcontinuous infusion; extended infusion; adverse events; pharmacokinetics; pharmacodynamics.antiinfective agent[SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitologypriority journaldisease severitybeta-Lactamstatistical model Agedprospective studyHumanMicrobiology (medical)medicine.medical_specialtydrug exposureCritical IllnessImmunologybloodstream infectionMicrobial Sensitivity Testspiperacillin plus tazobactambeta-LactamsMicrobiologybeta lactam abdominal infection03 medical and health sciencescritically ill patientIntensive careAnti-Bacterial AgentcefepimepharmacodynamicsHumansDosingAdverse effectAgedModels Statistical030306 microbiologyOdds ratiomajor clinical studymortalityantibiotic sensitivityceftriaxoneProspective Studiemulticenter studypharmacodynamics.ampicillinBlood Chemical AnalysisCeftazidimeSettore MED/41 - AnestesiologiaInterquartile rangelaw030212 general & internal medicinepharmacokineticlung infectionMicrobial Sensitivity TestarticleBacterial InfectionsMiddle AgedStatisticalcontinuous infusionIntensive care unitAnti-Bacterial Agentsextended infusionIntensive Care UnitsInfectious DiseasesTreatment Outcomeadverse events; continuous infusion; extended infusion; pharmacodynamics; pharmacokinetics; Aged; Anti-Bacterial Agents; Bacterial Infections; Blood Chemical Analysis; Female; Humans; Intensive Care Units; International Cooperation; Male; Microbial Sensitivity Tests; Middle Aged; Models Statistical; Prospective Studies; Treatment Outcome; beta-Lactams; Critical Illness; Microbiology (medical); Infectious Diseasescefazolin[SDV.IMM]Life Sciences [q-bio]/Immunologyblood samplingFemalepharmacokineticsmedicine.drugmedicine.drug_classprevalencedoripenemminimum inhibitory concentrationBacterial InfectionInternal medicinemedicinecontrolled studyblood analysibusiness.industryBlood Chemical Analysiadverse eventsSurgerypharmacodynamicdrug blood levelbusiness
researchProduct

Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (C…

2019

Background and aims Limited data are available on the effectiveness and tolerability of direct-acting antivirals (DAAs) therapies in the real world for HCV-infected patients with comorbidities. This study aimed to describe the effectiveness of OBV/PTV/r +/- DSV (3D/2D regimen) with or without ribavirin (RBV) in HCV or HCV/HIV co-infected patients with GT1/GT4 and CKD (IIIb-V stages), including those under hemodialysis and peritoneal dialysis in routine clinical practice in Spain in 2015. Material and methods Non-interventional, retrospective, multicenter data collection study in 31 Spanish sites. Socio-demographic, clinical variables, study treatment characteristics, effectiveness and toler…

Malemedicine.medical_treatmentHIV InfectionsHepacivirus0302 clinical medicine:Infections::Virus Diseases::Hepatitis Viral Human::Hepatitis C::Hepatitis C Chronic [DISEASES]ribavirina2-Naphthylaminemediana edad:virosis::infecciones por virus ARN::infecciones por Retroviridae::infecciones por Lentivirus::infecciones por VIH [ENFERMEDADES]ancianoSulfonamidesCoinfectionfarmacoterapiaLiver Diseasesvirus diseasesValineInfeccions per VIH - TractamentCirrhosisNephrology/drug therapyMedicine030211 gastroenterology & hepatologyDrug Therapy Combinationinsuficiencia renalmedicine.medical_specialty:virosis::hepatitis viral humana::hepatitis C::hepatitis C crónica [ENFERMEDADES]GenotypeProlineSciencecompuestos macrocíclicosSurgical and Invasive Medical ProceduresGastroenterology and HepatologyAntiviral AgentsMicrobiologyUrinary System ProceduresPeritoneal dialysis03 medical and health sciencesDrug TherapyHumansLost to follow-upRenal Insufficiency ChronicUracilAgedRetrospective StudiesFlavivirusesanilidasOrganismsOrgan Transplantationmedicine.diseasedigestive system diseasesRegimenchemistryHIV-1Malalties del ronyóCarbamatesgenotipoCyclopropanesRNA virusesantivíricosSustained Virologic ResponsePhysiologyhumanoschemistry.chemical_compoundChronic Kidney DiseaseMedicine and Health SciencesRenal TransplantationAnilidesRenal Insufficiency030212 general & internal medicinePathology and laboratory medicinecoinfecciónMultidisciplinaryKidney diseasesHepatitis C virus:Infections::Infections::Virus Diseases::RNA Virus Infections::Retroviridae Infections::Lentivirus Infections::Infections::Virus Diseases::HIV Infections [DISEASES]resultado del tratamientoQR:Infections::Coinfection [DISEASES]Middle AgedMedical microbiologyHepatitis CTreatment OutcomeInfectious DiseasesTolerabilityResearch DesigncarbamatosVirusesFemaleHemodialysisPathogensVIH-1Research ArticleGlomerular Filtration RateMacrocyclic CompoundsClinical Research DesignLactams MacrocyclicResearch and Analysis MethodssulfonamidasRenal DialysisInternal medicineRibavirinMedical DialysismedicineDialysisTransplantationRenal Physiology/tratamiento farmacológicoRitonavirBiology and life sciencesbusiness.industryRibavirinestudios retrospectivosViral pathogensHepatitis C ChronicHepatitis virusesMicrobial pathogens:enfermedades parasitarias::coinfección [ENFERMEDADES]Spaindiálisis renalCo-InfectionsPhysical therapyinfecciones por VIHAdverse EventsbusinessHepatitis C - TractamenturaciloKidney diseasePLoS ONE
researchProduct

Therapeutic Strategies To Counteract Antibiotic Resistance in MRSA Biofilm‐Associated Infections

2021

Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as one of the leading causes of persistent human infections. This pathogen is widespread and is able to colonize asymptomatically about a third of the population, causing moderate to severe infections. It is currently considered the most common cause of nosocomial infections and one of the main causes of death in hospitalized patients. Due to its high morbidity and mortality rate and its ability to resist most antibiotics on the market, it has been termed a “superbug”. Its ability to form biofilms on biotic and abiotic surfaces seems to be the primarily means of MRSA antibiotic resistance and pervasiveness. Importantly, more tha…

Methicillin-Resistant Staphylococcus aureusmedicine.medical_specialtymedicine.drug_classMRSA biofilm antibiotic-resistance antivirulence strategy eradicating agentsAntibioticsPopulationbeta-Lactamsmedicine.disease_cause01 natural sciencesBiochemistryHigh morbidityAntibiotic resistanceDrug Resistance BacterialDrug DiscoveryHumansMedicineGeneral Pharmacology Toxicology and PharmaceuticsIntensive care medicineeducationProtein Kinase InhibitorsPathogenOxazolidinonesPharmacologyeducation.field_of_study010405 organic chemistrybusiness.industryMortality rateOrganic ChemistryBiofilmStaphylococcal Infectionsbiochemical phenomena metabolism and nutritionAnti-Bacterial Agents0104 chemical sciences010404 medicinal & biomolecular chemistryStaphylococcus aureusBiofilmsPhenazinesMolecular MedicinebusinessChemMedChem
researchProduct

Sequence type 101 (ST101) as the predominant carbapenem-non-susceptible Klebsiella pneumoniae clone in an acute general hospital in Italy.

2012

Klebsiella pneumoniae is one of the most common multidrug-resistant (MDR) Gram-negative organisms worldwide, responsible for high morbidity and mortality both in hospitals and alternative healthcare settings. Recently, increasing use of carbapenems has promoted the emergence and dissemination of carbapenem-non-susceptible MDR K. pneumoniae strains. All of the CNSKP strains isolated between January 2009 and December 2011 in the General Hospital of Prato (Prato, Italy) were studied. Our findings indicate that, unlike previously reported by other authors from different regions of Italy, K. pneumoniae producing KPC-2 and belonging to ST101 have been established in the area of Prato, Tuscany, It…

Microbiology (medical)CarbapenemSettore MED/07 - Microbiologia E Microbiologia ClinicaKlebsiella pneumoniaeClone (cell biology)Drug resistanceMicrobial Sensitivity TestsSettore MED/42 - Igiene Generale E ApplicataHospitals Generalbeta-LactamsMicrobiologyDrug Resistance BacterialmedicineHumansPharmacology (medical)General hospitalhospitalSequence (medicine)Cross InfectionbiologyGeneral Medicinebiology.organism_classificationST101Anti-Bacterial AgentsKlebsiella InfectionsImipenemKlebsiella pneumoniaeInfectious DiseasesCarbapenemsItalymedicine.drugInternational journal of antimicrobial agents
researchProduct

New β-Lactam-β-Lactamase Inhibitor Combinations.

2020

The limited armamentarium against drug-resistant Gram-negative bacilli has led to the development of several novel β-lactam-β-lactamase inhibitor combinations (BLBLIs). In this review, we summarize their spectrum of in vitro activities, mechanisms of resistance, and pharmacokinetic-pharmacodynamic (PK-PD) characteristics. A summary of available clinical data is provided per drug. Four approved BLBLIs are discussed in detail. All are options for treating multidrug-resistant (MDR) Enterobacterales and Pseudomonas aeruginosa Ceftazidime-avibactam is a potential drug for treating Enterobacterales producing extended-spectrum β-lactamase (ESBL), Klebsiella pneumoniae carbapenemase (KPC), AmpC, an…

Microbiology (medical)DrugImipenemBacilliEpidemiologyKlebsiella pneumoniaemedia_common.quotation_subjectMicrobial Sensitivity Testsmedicine.disease_causebeta-LactamsMeropenemMicrobiologyDrug Resistance Multiple BacterialGram-Negative Bacteriapolycyclic compoundsmedicinemedia_commonGeneral Immunology and MicrobiologybiologyPseudomonas aeruginosabusiness.industryPublic Health Environmental and Occupational Healthbiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationCeftazidime/avibactamAcinetobacter baumanniiDrug CombinationsInfectious DiseasesbacteriaErratumbusinessbeta-Lactamase Inhibitorsmedicine.drugClinical microbiology reviews
researchProduct

Synthesis of enantiopure pyrrolidine-derived peptidomimetics and oligo-beta-peptides via nucleophilic ring-opening of beta-lactams.

2006

The synthesis of the two enantiomers of pyrrolidine-derived spiro beta-lactams by resolution with D- and L-Boc phenylalanine is described. The potential of these optically active spiro beta-lactams on the synthesis of peptidomimetics as analogues of melanostatin is evaluated. Theoretical studies of several models, at the Becke3LYP/6-31+G* level of theory, together with previous experimental evidences from our group, gathered by NMR, allow us to design structures that can efficiently mimic some biologically active peptide-type molecules. On the other hand, the spiro beta-lactams have shown their utility in the preparation of beta-peptides. As an example, a homo-tetra-beta-peptide was synthes…

Models MolecularMagnetic Resonance SpectroscopyPyrrolidinesPeptidomimeticStereochemistryStereoisomerismRing (chemistry)beta-LactamsChemical synthesisPyrrolidinechemistry.chemical_compoundNucleophileβ lactamschemistry.chemical_classificationOrganic ChemistryMolecular MimicryStereoisomerismNuclear magnetic resonance spectroscopyGeneral MedicineMSH Release-Inhibiting HormoneAmino acidEnantiopure drugchemistryDrug DesignLactamOligopeptidesThe Journal of organic chemistry
researchProduct

Role of Protein Flexibility in Enzymatic Catalysis:  Quantum Mechanical−Molecular Mechanical Study of the Deacylation Reaction in Class A β-Lactamases

2002

We present a theoretical study of a mechanism for the hydrolysis of the acyl-enzyme complex formed by a class A beta-lactamase (TEM1) and an antibiotic (penicillanate), as a part of the process of antibiotic's inactivation by this type of enzymes. In the presented mechanism the carboxylate group of a particular residue (Glu166) activates a water molecule, accepting one of its protons, and afterward transfers this proton directly to the acylated serine residue (Ser70). In our study we employed a quantum mechanics (AM1)-molecular mechanics partition scheme (QM/MM) where all the atoms of the system were allowed to relax. For this purpose we used the GRACE procedure in which part of the system …

Models MolecularProtonAcylationHydrolysisProtonationGeneral Chemistrybeta-LactamsBiochemistryProtein Structure Secondarybeta-LactamasesCatalysisAnti-Bacterial AgentsEnzyme catalysisCatalysisAdductchemistry.chemical_compoundResidue (chemistry)Colloid and Surface ChemistrychemistryComputational chemistryQuantum TheoryThermodynamicsMoleculeCarboxylateJournal of the American Chemical Society
researchProduct

Inside the Hsp90 inhibitors binding mode through induced fit docking

2009

Abstract During the last few decades, the development of new anticancer strategies had to face the instability of many tumors, occurring when the genetic plasticity of cells produces new drug-resistant cancers. It has been shown that a chaperone protein, heat shock protein 90 (Hsp90), is one of the fundamental factors involved in the cell response to stresses, and its role in many biochemical pathways has been demonstrated. Thus, the inhibition of Hsp90 represents a new target of antitumor therapy, since it may influence many specific signaling pathways. The natural antibiotic Geldanamycin is the first Hsp90 inhibitor that has been identified. Nevertheless, more potent and water-soluble sma…

Models MolecularStereochemistryLactams MacrocyclicMolecular Sequence DataComputational biologyCrystallography X-RayLigandsHsp90 inhibitorchemistry.chemical_compoundAdenosine TriphosphateHeat shock proteinCatalytic DomainMaterials ChemistryBenzoquinonesAmino Acid SequenceHSP90 Heat-Shock ProteinsPhysical and Theoretical ChemistrySpectroscopyInduced fitBinding SitesbiologyMolecular StructureHeat shock proteinDrug discoveryActive siteGeldanamycinRadicicolComputer Graphics and Computer-Aided DesignSmall moleculeHsp90Settore CHIM/08 - Chimica FarmaceuticachemistryDocking (molecular)Molecular dockingbiology.proteinGeldanamicynSequence AlignmentProtein Binding
researchProduct